{"entity":{"id":"nct07601048","kind":"trial","name":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","aka":[],"tldr":"A phase 3 trial of Fulzerasib, Garsorasib and Glecirasib in Non-small-cell lung cancer, run by Shandong Suncadia Medicine Co., Ltd., not yet recruiting.","summary":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment is a phase 3 interventional study registered as NCT07601048 by Shandong Suncadia Medicine Co., Ltd., with 450 participants planned, started 2026-06 and due to reach its primary completion in 2028-05. Interventions recorded: HRS-7058, Fulzerasib Tablets, Garsorasib Tablets, Glecirasib Citrate Tablets. Conditions recorded: KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment.\n\nLinked to the drug Fulzerasib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.","status":"planned","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07601048","url":"https://clinicaltrials.gov/study/NCT07601048"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","kras-g12c-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["fulzerasib","garsorasib","glecirasib"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07601048","phase":"3","setting":"A Randomized, Open-Label, Multicenter Phase III Trial of HRS-7058 Versus the Investigator-Selected KRAS G12C Inhibitor in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","sponsor":"Shandong Suncadia Medicine Co., Ltd.","participation":[{"nct":"NCT07601048","source":"https://clinicaltrials.gov/study/NCT07601048","fetchedAt":"2026-10-07T16:55:50.238Z","studySha256":"d4585b632786b5847600b09566c86515bfc6b165d8da1bb9876404f3e0fac49d","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-05-22","leadSponsor":"Shandong Suncadia Medicine Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":450,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2026-06","startedType":"estimated","enrolled":450,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07601048/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/"},{"id":"garsorasib","kind":"drug","name":"Garsorasib","route":"/drugs/garsorasib/"},{"id":"glecirasib","kind":"drug","name":"Glecirasib","route":"/drugs/glecirasib/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}